early automatic multichannel analyzers. Scant consideration has been given to the most relevant tests to perform for a given species. With the advent of more modem analyzers, which offer greater flexibility in the choice of tests, this affords an opportunity for a more rational approach to be reflected in the guidelines. Thus, the climate was considered right for reevaluation of the clinical biochemistry requirements in the OECD guidelines. The trigger for this reevaluation came from a commentary made in March 1988 by Professor Dennis Baron, a member of the UK Medicines Commission and former Professor of Chemical Pathology. His commentary can be summarized as follows:
Whilst the regulatory authorities demand the present uncritical batch of tests, pharmaceutical companies, contract laboratories and other investigators are bound to provide them. This document is an attempt to initiate discussion with regulatory authorities that they should think again. In my view, clinical biochemistry guidelines in respect of tests for drug toxicity on experimental animals (and also on human subjects) are outdated. They also involve a concept of multichannel analyzer investigation that is no longer applicable-fixed profiling as a substitute for thought.
In terms of the review process, a subgroup was formed with Professor Baron and various members of the Animal Clinical Chemistry Association in the UK of which I was a member. This subgroup, after its deliberations, put forward recommendations to the UK OECD Shadow Toxicology Group under the chairmanship of Dr. Robin Fielder, who is also the OECD Coordinator for toxicity guidelines in the UK. This group, which consists of various members drawn from academia, government, and industry (including myself, is involved in the review of OECD toxicology guidelines. The Foremost amongst these criteria was the approach that should be taken. This is very fundamental to our discussion at this International Workshop; whether or not we should be adopting some form of tiered approach that says there is an initial screening phase, and depending on what you find in that screening phase, there is some follow-up that may be needed to characterise that effect. The need for functional indices in addition to indicators of damage was discussed. For example, liver enzymes are not indicators of &dquo;liver function,&dquo; as some medics would have us believe. Assessment of the functional capacity of the liver can be made by estimating the hepatic clearance of exogenous dyes or by measuring the plasma concentration of endogenous bile acids. The flexibility of the requirements was discussed because in the UK we feel that the guidelines should be less rigid. Many of the other criteria that were discussed have already been addressed earlier in this Workshop (e.g., sampling site, use of serum or plasma-a perennial dilemma). Finally, we discussed whether any obvious measurements should be added to or deleted from the list.
From a discussion of these criteria, 4 controversial issues were included in our recommendations.
First, the need for fasting animals prior to the collection of blood for clinical biochemistry measurements was not seen as essential in a screening approach. In fact, many of the group felt that we should be measuring nonfasting glucose in the first instance, since this was often a more sensitive measure than fasting glucose. However, the importance of fasting for a more in-depth investigation of a particular effect on carbohydrate or lipid metabolism was recognised. Second, the availability of adequate and validated methods for the measurement of total bile acids was considered sufficiently advanced to warrant the inclusion of this end point as an index of hepatic function. Third, the benefits of blood sampling during the in-life phase of a subchronic study, rather than just at termination, when pathological evaluation of tissues was available, were considered to exploit the strengths of clinical biochemistry and to provide additional screening information of value. Fourth, the inclusion of urinalysis in screening studies was considered to be justified since it has the potential not only to provide information on the urinary tract, especially on the kidney, but also to reflect other systemic changes. Furthermore, there is a case to be made that urinalysis is important not in chronic studies, as some guidelines suggest, but certainly in shorter-duration studies, when the problems of geriatric nephropathy are less evident.
The recommendations of the UK group have now been discussed by the OECD UK Shadow Group on Toxicology and are embodied in the clinical biochemistry sections of the OECD guidelines that have been submitted by the UK group to other OECD members. The recommendations of the UK group are reproduced here:
Clinical biochemistry determinations to investigate major toxic effects in tissues and specifically effects on kidney and liver should be performed on blood samples obtained just prior to or as part of the termination procedure. Investigations of plasma or serum shall include sodium, potassium, non-fasting glucose, total cholesterol, urea, creatinine, total protein and albumin, alanine aminotransferase [EC 2.6.1.2] activity, bile acids and total bilirubin. Additional enzyme measurements (of hepatic or other origin) may provide useful information under certain circumstances. The following urinalysis investigations should be performed under the conditions of water deprivation (at least 6 hours)-it is preferable to collect urine over ice (at 0°C) or with some preservative : appearance, volume, osmolality or specific gravity, microscopic examination of the urinary sediment, pH, total protein (NB The 'dipstick' method is of limited value since many low molecular weight proteins are less well detected), glucose and blood cells. Other useful information may be obtained by measuring urinary enzymes of renal origin and specific tests of renal function.
In addition, studies should be considered to investigate serum markers of general tissue damage. Other determinations that should be carried out if the known properties of the test substance may, or are suspected to, affect related metabolic profiles include calcium, phosphate, fasting triglycerides and fasting glucose, specific hormones, methaemoglobin and cholinesterase. These need to be identified on a case by case basis.
Overall there is a need for a flexible approach, depending on the species and the observed and/or expected effect with a given substance.
If historical baseline data are inadequate, consideration should be given to determination of clinical biochemistry analytes before dosing commences.
In making these recommendations, it is recognised that some may be regarded as provocative; however, this is, I believe, vital to a healthy and vigorous debate of the merits of what to measure and what not to measure and, most importantly, when to make the measurements. Clinical biochemistry requirements in toxicity guidelines cannot be considered in isolation but must form part of a coherent approach to the testing strategy. The need for a certain degree of flexibility and judgement in what should be measured is of paramount importance in this approach. Strict adherence to a list of prescribed measurements, some of which are either not applicable or completely irrelevant, benefits neither those who provide the data nor those who receive the data.
DISCUSSION
Dr. Gross. I need to make one comment here. I worked with guidelines (EPA) in 1977, which was not so recently, and we did not work in a vacuum.
We tried to reflect the best science that was available at the time. We asked for comments, we reviewed them very carefully, and so forth, including those from the OECD; I worked with some of that, too. There is a misconception that we work in this vacuum and that we are just throwing things at people, when in fact, we are not.
Dr. Loeb. With respect to the urine examination, in what species was that conducted and how were the samples collected?
Dr. Stonard. It was either from a rodent or a nonrodent species. Most commonly, the work was done in the rat.
Dr. Loeb. How were these samples collected? Dr. Stonard. The period over which they were collected varied from 4 hr up to 24 hr. My own preference, for example, is to collect over a preservative, if that is the type of thing you are asking.
Dr. Loeb. That is very much the type of thing I am asking.
Dr. Stonard. Well, I can only tell you what we do in our laboratory. We use sodium azide as a preservative, and we have not found interference in any of the analyses that we routinely measure or in those that we have had occasion to use in more of a research mode.
